# Combination Chemotherapy Following Surgery in Treating Patients With Urinary Tract Cancer

> **NCT00028860** · PHASE2 · COMPLETED · sponsor: **Tulane University Health Sciences Center**

## Conditions studied

- Bladder Cancer
- Transitional Cell Cancer of the Renal Pelvis and Ureter

## Interventions

- **BIOLOGICAL:** filgrastim
- **DRUG:** carboplatin
- **DRUG:** gemcitabine hydrochloride
- **DRUG:** ifosfamide
- **DRUG:** paclitaxel
- **PROCEDURE:** adjuvant therapy

## Key facts

- **NCT ID:** NCT00028860
- **Lead sponsor:** Tulane University Health Sciences Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-10
- **Primary completion:** —
- **Final completion:** 2004-10
- **Target enrollment:** — (—)
- **Last updated:** 2013-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00028860

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00028860, "Combination Chemotherapy Following Surgery in Treating Patients With Urinary Tract Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00028860. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*